- MCI One (DRDR) has completed its acquisition of all the issued and outstanding shares of Khure Health
- Khure’s precision medicine platform harnesses clinical data, enabling physicians to rapidly screen and identify patients with rare diseases
- The acquisition will enhance MCI’s data analytics offering
- MCI acquired 100 per cent of the issued and outstanding shares of Khure for up to C$13.5 million based on certain revenue milestones being achieved
- MCI Onehealth is up 5.00 per cent on the day, with shares trading at $3.15 at 1:23 pm ET
MCI One (DRDR) has completed its acquisition of all the issued and outstanding shares of Khure Health.
Khure’s precision medicine platform harnesses clinical data, enabling physicians to rapidly screen and identify patients with rare diseases and facilitate more personalized treatment.
The acquisition will enhance MCI’s data analytics offering through Khure’s continued work with leading pharmaceutical and medical device companies in North America, Europe and Japan.
MCI acquired 100 per cent of the issued and outstanding shares of Khure for up to C$13.5 million based on certain revenue milestones being achieved through calendar 2023.
Khure is actively working with or has rare and specialty disease programs in development with top 10 Pharma companies and international disease associations.
“By adding our clinical intelligence platform to MCI’s growing operations in primary care and healthcare technologies, we believe that our shared goals of better understanding and diagnosing rare diseases among Canadians will advance substantially,” said Khure President Don Watts.
MCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs.
MCI Onehealth is up 5.00 per cent on the day, with shares trading at $3.15 at 1:23 pm ET.